China Contract Research Organization (CRO) Industry Report, 2013-2016
  • May 2014
  • Hard Copy
  • USD $2,000
  • Pages:85
  • Single User License
    (PDF Unprintable)       
  • USD $1,900
  • Code: ZLC003
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,950
  • Hard Copy + Single User License
  • USD $2,200
      

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share.

As China is full of talents, has advantage of relatively low costs and is rich in disease spectrum, the world’s renowned CRO companies, including Quintiles, Covance, Parexel and Charles River, have entered the Chinese market through sole proprietorship, corporation or acquisition, driving the industry towards standardization to some extent.

At present, there are about 500 companies involved in CRO market in China, but only a few of them are operating at scale and in good shape. WuXi AppTec, ShangPharma Corp, Asymchem and Hangzhou Tigermed Consulting Co., Ltd. Are the leading local CRO companies in China, together holding around 15% of China CRO market.

WuXi AppTec is the largest local CRO player in China, making up about 10% of China CRO market; Hangzhou Tigermed Consulting Co., Ltd. is the only local CRO company listed in China, whose revenue has increased at a rate of above 30% annually over the last three years; Asymchem Inc. takes medical CMO as primary business, with its revenue arriving at RMB 542.8 million in 2013, and has embarked on IPO.

In order to share resources and improve overall competitiveness, some Chinese CRO companies are realizing mutual development by creating alliances, such as Alliance of Biotechnology Outsourcing (or ABO, including 38 companies such as Sino Biological Inc. and Pharmaron). In 2013, the revenue of ABO topped RMB 2 billion, up 11% from a year ago, of which RMB 1 billion came from international services.

?CRO 英文_副本.jpg

China Contract Research Organization (CRO) Industry Report 2013-2016 highlights the following:
20120114.gifStatus quo, market size, competitive landscape, market characteristics and trend of China CRO industry;
20120114.gifInternational environment, industry environment and policy environment of China CRO industry;
20120114.gifOperation, development in China and outlook of 5 global and 9 Chinese CRO companies.

1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2. Overview of China CRO Market
2.1 Status Quo
2.2 Market Size
2.3 Competitive Landscape
2.4 Market Characteristics
2.5 Trends
2.5.1 Improvement of Industrial Chain
2.5.2 Internationalization of Qualification Certification Standard
2.5.3 Development Driven by Technical Innovation

3. Development Environment of China CRO Industry
3.1 International Environment
3.1.1 Development History
3.1.2 Development Status Quo
3.1.3 Industry Status Quo
3.2 Industry Environment
3.3 Regional Market
3.3.1 Beijing
3.3.2 Shanghai
3.3.3 Chengdu
3.4 Policy Environment

4. Key Foreign CRO Companies
4.1 Covance
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Development in China
4.2 Parexel
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Development in China
4.3 PPD
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Development in China
4.4 Quintiles
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Development in China
4.5 Charles River
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Development in China

5. Key Chinese CRO Players
5.1 Wuxi AppTec
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Investment
5.1.6 Forecast and Outlook
5.2 Hangzhou Tigermed Consulting Co., Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Forecast and Outlook
5.3 ShangPharma Corp
5.3.1 Profile
5.3.2 Operation
5.3.3 Gross Margin
5.4 Venturepharm Laboratories Limited
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.5 Asymchem
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Forecast and Outlook
5.6 Other Companies
5.6.1 Shanghai Mediclon Inc.
5.6.2 Sundia MediTech Company Ltd.
5.6.3 Guangzhou Yushi Medicinal Technology Co., Ltd.
5.6.4 Guangzhou Boji Medical Biotechnological Co., Ltd. 

6. Conclusion and Forecast
6.1 Size of China CRO Market
6.2 Operation Comparison of CRO Companies in China
6.2.1 Revenue
6.2.2 Net Income
6.2.3 Gross Margin
Classification of Pharmaceutical Outsourcing
R&D Process of New Drug
Market Size of China CRO Industry, 2007-2013
Market Share of Major Chinese CRO Companies, 2013
Sales and Profit of Global Top 10 Pharmaceutical Companies, 2013
Size and Growth Rate of Global CRO Market, 2006-2013
Distribution of Major Foreign CRO Companies in China
Number and Growth Rate of Companies in China Pharmaceutical Manufacturing Industry, 2000-2013
Revenue and Growth Rate of China Pharmaceutical Manufacturing Industry, 2000-2013
Total Profit and Growth Rate of China Pharmaceutical Manufacturing Industry, 2000-2013
Amount of Investment Attraction by Beijing Biomedical Industry, 2008-2013
Sales Revenue and YoY Growth Rate of ABO, 2010-2013
Revenue from International Orders and YoY Growth Rate of ABO, 2010-2013
Initiators of Zhongguancun CRO Alliance (Listed Alphabetically)
Platform Advantages of Zhangjiang Drug Valley
List of Major CRO Companies in Zhangjiang Drug Valley
Policies Concerning China CRO Industry
Net Revenue and Net Income of Covance, 2009-2013
Net Revenue of Covance by Business, 2009-2013
Net Revenue Structure of Covance by Business, 2009-2013
Gross Margin of Covance, 2009-2013
Revenue from Services and Net Income of Parexel, 2009-2013
Revenue from Services of Parexel by Product, 2009-2013
Revenue from Services of Parexel by Region, 2009-2013
Structure of Revenue from Services of Parexel by Product, 2009-2013
Structure of Revenue from Services of Parexel by Region, 2009-2013
Net Revenue and Net Income of PPD, 2008-2011
Net Revenue of PPD by Source, 2008-2011
Net Revenue Structure of PPD by Source, 2008-2011
Total Revenue and Net Income of Quintiles, 2010-2013
Revenue of Quintiles by Product, 2009-2013
Total Revenue Structure of Quintiles by Product, 2009-2013
Revenue Structure of Quintiles by Region, 2010-2013
Gross Margin of Quintiles, 2010-2013
Net Sales and Net Income of Charles River, 2009-2013
Net Sales Structure of Charles River by Product, 2011-2013
Net Sales Structure of Charles River by Region, 2010-2013
Gross Margin of Charles River, 2009-2013
Business Areas Distribution of WuXi AppTec
Net Revenue and Net Income of WuXi AppTec, 2009-2013
Revenue Structure of WuXi AppTec by Product, 2009-2013
Revenue Structure of WuXi AppTec by Division, 2012-2013
Revenue Structure of WuXi AppTec by Areas Where Customers Are Located, 2009-2013
Gross Margin of WuXi AppTec, 2009-2013
Gross Margin of WuXi AppTec by Product, 2009-2012
Net Revenue and Net Income of WuXi AppTec, 2012-2016E
Revenue and Net Income of Tigermed, 2009-2013
Revenue Structure of Tigermed by Product, 2009-2013
Revenue Structure of Tigermed by Region, 2009-2013
Gross Margin of Tigermed, 2009-2013
Gross Margin of Tigermed by Product, 2009-2013
Gross Margin of Tigermed by Region, 2009-2013
R&D Costs and % of Total Revenue of Tigermed, 2011-2013
Revenue and Net Income of Tigermed, 2012-2016E
Organizational Structure of ShangPharma
Revenue and Net Income of ShangPharma, 2009-2012
Gross Margin of ShangPharma, 2009-2012
Holding and Affiliate Companies of Venturepharm Laboratories
Revenue and Net Income of Venturepharm Laboratories, 2009-2013
Revenue Structure of Venturepharm Laboratories by Product, 2009-2013
Gross Margin of Venturepharm Laboratories, 2009-2013
Revenue and Net Income of Asymchem, 2011-2013
Revenue Structure of Asymchem by Item, 2011-2013
Gross Margin of Asymchem, 2011-2013
R&D Costs and % of Total Revenue of Asymchem, 2011-2013
Asymchem’s Major Subsidiaries
Orders Won by Asymchem by Type, 2011-2013
Proposed Projects with Funds Raised From Upcoming IPO in May 2014
Revenue and Net Income of Asymchem, 2011-2016E
Market Size of China CRO Industry, 2007-2016E
Revenue of Major Companies in China CRO Industry, 2009-2013
Revenue Growth Rate of Major Companies in China CRO Industry, 2010-2013
Net Income of Major Companies in China CRO Industry, 2009-2013
Net Profit Margin of Major Companies in China CRO Industry, 2009-2013
Gross Margin of Major Companies in China CRO Industry, 2009-2013

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统